EGFR and non-small cell lung carcinoma: Personalized medicine revolutionized NS-NSCLC in 2004, with the discovery that specific mutations in the epidermal growth factor receptor (EGFR) sensitized tumors to a targeted treatment with the tyrosine kinase inhibitors (TKI) erlotinib and gefitinib [5,6,7].